Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
- PMID: 32289548
- PMCID: PMC7151271
- DOI: 10.1016/j.tmaid.2020.101663
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Abstract
Background: We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration.
Methods: We conducted an uncontrolled, non-comparative, observational study in a cohort of 80 relatively mildly infected inpatients treated with a combination of hydroxychloroquine and azithromycin over a period of at least three days, with three main measurements: clinical outcome, contagiousness as assessed by PCR and culture, and length of stay in infectious disease unit (IDU).
Results: All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days.
Conclusion: We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.
Keywords: Azithromycin; COVID-19; Culture; Hydroxychloroquine; PCR; SARS-CoV-2.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Figures


Comment in
-
Practical implementation of COVID-19 patient flags into an antimicrobial stewardship program's prospective review.Infect Control Hosp Epidemiol. 2020 Sep;41(9):1108-1110. doi: 10.1017/ice.2020.133. Epub 2020 Apr 15. Infect Control Hosp Epidemiol. 2020. PMID: 32290883 Free PMC article. No abstract available.
-
Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist.Ann Rheum Dis. 2020 Jun;79(6):734-736. doi: 10.1136/annrheumdis-2020-217480. Epub 2020 Apr 15. Ann Rheum Dis. 2020. PMID: 32295786 Free PMC article. No abstract available.
-
[Covid-19: care protocols or research protocols?].Med Sci (Paris). 2020 May;36(5):521-523. doi: 10.1051/medsci/2020107. Epub 2020 May 15. Med Sci (Paris). 2020. PMID: 32452375 French. No abstract available.
-
Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.Travel Med Infect Dis. 2020 Sep-Oct;37:101826. doi: 10.1016/j.tmaid.2020.101826. Epub 2020 Jul 31. Travel Med Infect Dis. 2020. PMID: 32739472 Free PMC article. No abstract available.
-
Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.Travel Med Infect Dis. 2020 Nov-Dec;38:101881. doi: 10.1016/j.tmaid.2020.101881. Epub 2020 Sep 18. Travel Med Infect Dis. 2020. PMID: 32956851 Free PMC article. No abstract available.
References
-
- WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re...
-
- Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020 - PubMed
-
- Coronavirus COVID-19 global cases by the center for systems science and engineering (CSSE) at johns Hopkins University (JHU) https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594... accessed on March, 26th, 2020 from.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous